These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38844134)

  • 1. PPARα phosphorylation regulates colorectal tumor immune escape.
    Gou Q; Tian X; Dong C; Yan B; Chen M; Shi J; Yang L; Hou Y
    J Biol Chem; 2024 Jul; 300(7):107447. PubMed ID: 38844134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Nuclear Receptor Coactivator SRC-1 Prevents Colorectal Cancer Immune Escape by Reducing Transcription and Protein Stability of PD-L1.
    Hong Y; Chen Q; Wang Z; Zhang Y; Li B; Guo H; Huang C; Kong X; Mo P; Xiao N; Xu J; Ye Y; Yu C
    Adv Sci (Weinh); 2024 Sep; 11(33):e2310037. PubMed ID: 38953362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
    Coelho MA; de Carné Trécesson S; Rana S; Zecchin D; Moore C; Molina-Arcas M; East P; Spencer-Dene B; Nye E; Barnouin K; Snijders AP; Lai WS; Blackshear PJ; Downward J
    Immunity; 2017 Dec; 47(6):1083-1099.e6. PubMed ID: 29246442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
    Zhang H; Xia Y; Wang F; Luo M; Yang K; Liang S; An S; Wu S; Yang C; Chen D; Xu M; Cai M; To KKW; Fu L
    Adv Sci (Weinh); 2021 May; 8(10):2003404. PubMed ID: 34026438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression.
    Khan B; Chen M; Wang H; Khan A; Hussain S; Shi J; Yang L; Hou Y
    Eur J Pharmacol; 2024 Jun; 972():176565. PubMed ID: 38599309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXP4-AS1 promotes CD8
    Shen GY; Zhang Y; Huang RZ; Huang ZY; Yang LY; Chen DZ; Yang SB
    Immunol Res; 2024 Aug; 72(4):766-775. PubMed ID: 38687433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
    Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer.
    Cen B; Wei J; Wang D; Xiong Y; Shay JW; DuBois RN
    Oncogene; 2021 Oct; 40(41):5984-5992. PubMed ID: 34385594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
    Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
    J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
    Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
    Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WTAP-induced N
    Liu QZ; Zhang N; Chen JY; Zhou MJ; Zhou DH; Chen Z; Huang ZX; Xie YX; Qiao GL; Tu XH
    Cancer Sci; 2024 Jun; 115(6):1749-1762. PubMed ID: 38508217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARγ inhibited tumor immune escape by inducing PD-L1 autophagic degradation.
    Gou Q; Che S; Chen M; Chen H; Shi J; Hou Y
    Cancer Sci; 2023 Jul; 114(7):2871-2881. PubMed ID: 37096255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
    Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
    Wang QM; Lian GY; Song Y; Huang YF; Gong Y
    Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation.
    Miao Z; Li J; Wang Y; Shi M; Gu X; Zhang X; Wei F; Tang X; Zheng L; Xing Y
    Mol Cancer; 2023 Dec; 22(1):205. PubMed ID: 38093288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression.
    Peng K; Liu Y; Liu S; Wang Z; Zhang H; He W; Jin Y; Wang L; Xia X; Xia L
    Cell Oncol (Dordr); 2024 Jun; 47(3):1043-1058. PubMed ID: 38315285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion.
    Voli F; Valli E; Lerra L; Kimpton K; Saletta F; Giorgi FM; Mercatelli D; Rouaen JRC; Shen S; Murray JE; Ahmed-Cox A; Cirillo G; Mayoh C; Beavis PA; Haber M; Trapani JA; Kavallaris M; Vittorio O
    Cancer Res; 2020 Oct; 80(19):4129-4144. PubMed ID: 32816860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade.
    Dai X; Bu X; Gao Y; Guo J; Hu J; Jiang C; Zhang Z; Xu K; Duan J; He S; Zhang J; Wan L; Liu T; Zhou X; Hung MC; Freeman GJ; Wei W
    Mol Cell; 2021 Jun; 81(11):2317-2331.e6. PubMed ID: 33909988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.